## Erica Zamberletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4987483/publications.pdf

Version: 2024-02-01

34 papers

1,440 citations

361045 20 h-index 29 g-index

34 all docs 34 docs citations

times ranked

34

2088 citing authors

#	Article	IF	CITATIONS
1	Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiology of Disease, 2015, 73, 60-69.	2.1	150
2	Adolescent exposure to cannabis as a risk factor for psychiatric disorders. Journal of Psychopharmacology, 2012, 26, 177-188.	2.0	125
3	Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiology of Disease, 2014, 63, 35-47.	2.1	120
4	Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology, 2011, 60, 235-243.	2.0	117
5	Gender-dependent behavioral and biochemical effects of adolescent delta-9-tetrahydrocannabinol in adult maternally deprived rats. Neuroscience, 2012, 204, 245-257.	1.1	101
6	Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats. European Neuropsychopharmacology, 2015, 25, 2404-2415.	0.3	86
7	The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. International Journal of Molecular Sciences, 2017, 18, 1916.	1.8	79
8	Adolescent THC exposure in female rats leads to cognitive deficits through a mechanism involving chromatin modifications in the prefrontal cortex. Journal of Psychiatry and Neuroscience, 2018, 43, 87-101.	1.4	58
9	Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. Frontiers in Cellular Neuroscience, 2019, 13, 367.	1.8	56
10	Endocannabinoids and Mental Disorders. Handbook of Experimental Pharmacology, 2015, 231, 261-283.	0.9	52
11	Long-term hippocampal glutamate synapse and astrocyte dysfunctions underlying the altered phenotype induced by adolescent THC treatment in male rats. Pharmacological Research, 2016, 111, 459-470.	3.1	51
12	Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. International Journal of Neuropsychopharmacology, 2011, 14, 17-28.	1.0	45
13	The Endocannabinoid System and Schizophrenia: Integration of Evidence. Current Pharmaceutical Design, 2012, 18, 4980-4990.	0.9	43
14	The phytocannabinoid, Δ <sup>9</sup> â€tetrahydrocannabivarin, can act through 5â€tetrahydrocannabivarin, can a	2.7	43
15	Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male <i>Mecp2</i> mutant mice. Journal of Psychopharmacology, 2019, 33, 894-907.	2.0	38
16	Sex-dependent changes in brain CB1R expression and functionality and immune CB2R expression as a consequence of maternal deprivation and adolescent cocaine exposure. Pharmacological Research, 2013, 74, 23-33.	3.1	36
17	Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. International Journal of Neuropsychopharmacology, 2012, 15, 267-280.	1.0	35
18	New vistas on cannabis use disorder. Neuropharmacology, 2017, 124, 62-72.	2.0	33

#	Article	IF	CITATIONS
19	Lifelong imbalanced LA/ALA intake impairs emotional and cognitive behavior via changes in brain endocannabinoid system. Journal of Lipid Research, 2017, 58, 301-316.	2.0	28
20	Adult Cellular Neuroadaptations Induced by Adolescent THC Exposure in Female Rats Are Rescued by Enhancing Anandamide Signaling. International Journal of Neuropsychopharmacology, 2018, 21, 1014-1024.	1.0	22
21	Remote memories are enhanced by COMT activity through dysregulation of the endocannabinoid system in the prefrontal cortex. Molecular Psychiatry, 2018, 23, 1040-1050.	4.1	19
22	Neurobiological mechanisms underlying cannabis-induced memory impairment. European Neuropsychopharmacology, 2020, 36, 181-190.	0.3	19
23	Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats. International Journal of Molecular Sciences, 2021, 22, 8899.	1.8	16
24	Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder., 2021, 226, 107878.		14
25	Chronic blockade of CB <sub>1</sub> receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. British Journal of Pharmacology, 2012, 167, 1652-1664.	2.7	12
26	Chronic FAAH inhibition during nicotine abstinence alters habenular CB1 receptor activity and precipitates depressive-like behaviors. Neuropharmacology, 2017, 113, 252-259.	2.0	12
27	The anabolic steroid nandrolone alters cannabinoid self-administration and brain CB1 receptor density and function. Pharmacological Research, 2017, 115, 209-217.	3.1	12
28	Dos(e)Age: Role of Dose and Age in the Long-Term Effect of Cannabinoids on Cognition. Molecules, 2022, 27, 1411.	1.7	9
29	Impact of Endocannabinoid System Manipulation on Neurodevelopmental Processes Relevant to Schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 616-626.	1.1	4
30	Cannabidiol/Phytocannabinoids: A New Opportunity for Schizophrenia Treatment?., 2014,, 526-537.		2
31	Pregnenolone-methyl-ether enhances CLIP170 and microtubule functions improving spine maturation and hippocampal deficits related to CDKL5 deficiency. Human Molecular Genetics, 2022, 31, 2738-2750.	1.4	2
32	Cannabidiol as a Potential Novel Therapeutic Agent for Psychotic Disorders., 2018,, 309-339.		1
33	Assay of GTPÎ <sup>3</sup> S Binding in Autoradiography. Methods in Molecular Biology, 2016, 1412, 95-101.	0.4	0
34	Daniela Parolaro, PhD (January 1, 1950–March 28, 2022). Cannabis and Cannabinoid Research, 2022, 7, 235-236.	1.5	0